Sunitinib in patients with metastatic renal cell carcinoma.

By R. Motzer, B. Rini, R. Bukowski, B. Curti, D. George, G. Hudes, B. Redman, K. Margolin, J. Merchan, G. Wilding and 5 more. Journal of the American Medical Association (JAMA), 2006

1,248 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/652c88e8ed1cf3fa06fc98d3c6ab7300a6b0fafe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. A. Adamis
2. N. Ferrara
3. D. McDonald
4. Daniel Chen
5. R. Apte

In Pulmonary and Respiratory Medicine

1. N. Ferrara

Citations in the corpus

• Molecular basis for sunitinib efficacy and future clinical development (2007, neutral): “In a pooled analysis of two independent, open-label Phase II studies of second-line sunitinib (summarized in Table 2 ), the objective response rate (ORR) was 42”
• Mechanisms of adverse effects of anti-VEGF therapy for cancer (2007, background): “In patients on sunitinib, hypertension had an incidence of 28% (6% had Grade 3) in phase II trials in metastatic renal cell carcinoma (Motzer et al, 2006) and an incidence of 15% (4% had Grade 3) in a phase III trial in GIST (Demetri et al, 2005).”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…in the MARINA and ANCHOR trials 207 , 208 , resulting in FDA approval for neovascular AMD • Sunitinib demonstrates anti-tumour activity as a second-line therapy in a Phase II trial on metastatic renal carcinoma 19,116,271 and in Phase I–III clinical trials for gastrointestinal stromal tumour 21 .”